As another clinically applicable example of combinatorial targeted therapy, Maertens et al. treated melanoma models harboring mutations (BRAF, NRAS, and NF1) with entinostat and BRAF/MEK inhibitors. The gene discussed is BRAF; the disease is melanoma.